Promising trials of malaria vaccine lead to calls for Phase 3 development

December 09, 2008

Potential for vaccines to be integrated into existing infant vaccination programs in sub-Saharan Africa

Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported today in the New England Journal of Medicine (NEJM).

In a separate paper, which also appears in the online journal today, the findings are presented of the first co-administration of the RTS, S/AS02 malaria vaccine through the WHO Expanded Program on Immunization (EPI) in infants living in an area of perennial transmission in Tanzania.

The RTS,S vaccine was invented, developed and manufactured by GlaxoSmithKline Biologicals, an active partner and the sponsor of the trials.

Funding and technical support for the studies was provided by the PATH Malaria Vaccine Initiative (MVI) through a grant provided by the Bill & Melinda Gates Foundation.

Malaria persists as a major public health problem, and new tools for control of the disease are needed to facilitate the current renewed commitment for its control or elimination.

The first paper reports on the findings of a double-blind randomized trial of a novel formulation of the malaria candidate vaccine (RTS/S/AS01E, which was invented, developed and manufactured by GSK Biologicals) conducted in Tanzania and Kenya by a team of international experts. 894 children aged between 5 and 17 months, a target population for vaccine licensure, were treated and followed up between 4.5 and 10 months.

A team from the London School of Hygiene & Tropical Medicine (LSHTM) including Lorenz von Seidlein, Reader in Clinical Epidemiology, Chris Drakeley, Senior Lecturer, clinical trials manager Jayne Gould, and Eleanor Riley, Professor of Immunology, all in the Department of Infectious Diseases, led the work in Korogwe, Tanzania in collaboration with Dr John Lusingu and colleagues from the Tanzanian National Institute for Medical Research. Dr Philip Bejon of the Kenya Medical Research Institute (KEMRI) Wellcome Collaborative Research Programme and the Centre for Tropical Medicine, University of Oxford, led similar efforts in Kilifi, Kenya.

Among the 835 children who were vaccinated according to protocol, estimated vaccine efficacy against clinical malaria was 53%. A strong immune response was detected, and the vaccine was safe. There were fewer serious adverse events among the RTS,S/AS01E vaccine recipients.

Based on the findings, the authors recommend a multi-centre Phase 3 trial of the RTS, S vaccine which will lead to an application for licensure if these findings are confirmed.

In a second paper, a team including David Schellenberg, Professor of Malaria & International Health at LSHTM, reports that a slightly different formulation of the vaccine candidate, which is being developed for delivery through the EPI, has a promising safety profile and does not react adversely with other antigens being administered as part of the immunization programme. The vaccine also showed a reduction in the incidence of malaria infection by 65%, a welcome but unexpected finding given that this was primarily designed as a safety and immunogenicity trial with only 340 infants enrolled.

Chris Drakeley comments: 'These two important papers add to the data on RTS,S, making a strong case for moving forward to large-scale vaccination in phase 3 trials. The formulation of RTS,S with the ASO1E adjuvant has improved vaccine efficacy considerably. Testing the vaccine in a broad range of epidemiological settings will show if it is suitable for inclusion in routine vaccination programmes throughout sub-Saharan Africa'.

Professor Riley recommends further investigation: 'In numerous trials, in different countries with differing levels of malaria risk, this vaccine has consistently protected young children against malaria infection and against clinical episodes of malaria, and the new ASO1E vaccine formulation has significantly enhanced the potency of the vaccine. However, we still don't have a clear idea of how the vaccine works and we don't yet have a laboratory test that will identify which vaccine recipients are fully protected.

Detailed immunological investigations of vaccine recipients and controls are now required to obtain a better understanding of the protective immune mechanisms that are induced and to obtain immunological correlates of protection'.

Professor Schellenberg comments: 'I'm delighted to have been able to support my colleagues at the Ifakara Health Institute in the conduct of this important study. It's the first time the vaccine has been given alongside routine vaccinations and we're really pleased to see that it was well tolerated, stimulated a detectable immune response and protected against malaria infection. The scene is now set for a larger-scale evaluation of the effect of this vaccine in a range of settings'.

Professor Sir Andrew Haines, Director of the London School of Hygiene & Tropical Medicine, concludes: 'The two malaria vaccine trials published in the New England Journal of Medicine this week demonstrate that substantial progress is being made in research to address one of the major global public health challenges - falciparum malaria. Both trials show promising efficacy of the candidate vaccines. One trial specifically looks at whether the vaccine in question can be co-administered with standard childhood vaccines delivered through the Expanded Programme and concludes that it does not appear to reduce the responses to these other vaccines. These results suggest that the way is now open to undertaking large scale Phase III trials in malaria endemic areas. I am delighted that Staff of the London School of Hygiene and Tropical Medicine have contributed substantially to this important research'.

London School of Hygiene & Tropical Medicine

The Elusive Malaria Vaccine: Miracle or Mirage?
by Irwin W. Sherman (Author)

Chronicling a 100-year quest, this book tells the fascinating story of the hunt for the still-elusive malaria vaccine. Its clear, engaging style makes the book accessible to a general audience and brings to life all the drama of the hunt, celebrating the triumphs and documenting the failures. The author captures the controversies, missteps, wars of words, stolen ideas, and clashes of ego as researchers around the world compete to develop the first successful malaria vaccine. The Elusive Malaria Vaccine: Miracle or Mirage? is based on author Irwin W. Sherman's thorough investigation of the scientific literature as well as his first-hand interviews with today's pioneers in malaria vaccine research. As a result, the book offers remarkable insights into the keys to a successful malaria...

Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program
by Committee on U.S. Military Malaria Vaccine Research - A Program Review (Author), Patricia M. Graves (Editor), Myron M. Levine (Editor)

Malaria: Waiting for the Vaccine
by G. A. T. Targett (Editor)

Malaria affects very large populations in tropical and sub-tropical areas of the world and the situation is now exacerbated by a growing resistance to drugs and insecticides by parasite and mosquito, respectively. Addresses the problem of public health management at the individual and community level, including the use and supply of drugs currently available as well as the economics of already strained health programs. The current status of vaccine development is assessed and recommendations are made for future research.

Control of Immune Response by Endocrine Factors Malaria Vaccine Controlled Drug Delivery Enzyme-Immunoassay (Progress in Clinical Biochemistry and Me)
by E. Debus (Author), C.J. Grossmann (Author), A.P. Hubbuch (Author), H.N. Lanners (Author), R. Linke (Author), Perkin (Author)

The demand for a malaria vaccine: evidence from Ethiopia [An article from: Journal of Development Economics]
by M.L. Cropper (Author), M. Haile (Author), J. Lampietti (Author), C. Poulos (Author), W (Author)

This digital document is a journal article from Journal of Development Economics, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
This study measures the monetary value households place on preventing malaria in Tigray, Ethiopia. We estimate a household demand function for a hypothetical malaria vaccine and compute the value of preventing malaria as the household's maximum willingness to pay to provide vaccines for all family members. This is contrasted with the traditional costs of illness (medical costs and lost productivity). Our results indicate that the value of preventing malaria with vaccines is about US$36 per household...

VICAL REPORTS POSITVE UPDATES FROM U.S. MILITARY MALARIA VACCINE.: An article from: Biotech Business
by Unavailable (Author)

This digital document is an article from Biotech Business, published by Worldwide Videotex on June 1, 2010. The length of the article is 443 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: VICAL REPORTS POSITVE UPDATES FROM U.S. MILITARY MALARIA VACCINE.
Author: Unavailable
Publication: Biotech Business (Newsletter)
Date: June 1, 2010
Publisher: Worldwide Videotex
Volume: 23 Issue: 6 Page: NA

Distributed by Gale, a part of Cengage...

Competitor Analysis: Malaria Vaccines
by La Merie Publishing (Author)

The present Competitive Intelligence Report about Malaria Vaccines provides a competitor evaluation in the field of investigational vaccines against one or more antigens of the Plasmodium (Pl) parasite, especiall of Pl. falciparum, for prophylaxis of Malaria as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Malaria is a mosquito-borne infectious disease caused by the Plasmodium parasite, especially Pl. falciparum. The parasite is transfected by the bite of a mosquito. Malaria is widespread in tropical and subtropical regions....

Body & brain.(2011 SCIENCE NEWS OF THE YEAR)(brain stents, malaria vaccines, and antidepressants and amyloid-beta's effects on Alzheimer's disease): An article from: Science News
by Unavailable (Author)

Gale Encyclopedia of Alternative Medicine: Malaria
by Mai Tran (Author)

The article is excerpted from Gale Encyclopedia of Alternative Medicine.
"Gale's products are known to be thorough, well-researched, and good reference tools. This item is no exception...
This is a valuable resource for readers who are seeking information on complementary medicine and herbal remedies. The scope of this encyclopedia is comprehensive, but not definitive. Readers should use this as a supplement,.to professional healthcare consultation. This source has been a long-awaited product for the consolidation of general alternative medicine information."
-- ARBA (2002) Can magnets relieve arthritis pain? Does the scent of lavender calm the nerves? Is St. John's Wort a mood enhancer? Authoritative, objective and in tune with the subjects that matter to...

Malaria: An entry from Thomson Gale's Gale Encyclopedia of Alternative Medicine
by Mai Tran (Author)

The term “Alternative Medicine” encompasses many forms, and elicits at least as many opinions. This authoritative, objective set is in tune with the subjects that matter to students and researchers, presenting four volumes of current, unbiased information on alternative and complementary medical practices. Covering all aspects of the subject—Therapies, Conditions/Diseases, Herbs/Plants and People—the “Gale Encyclopedia of Alternative Medicine” identifies 150 types of alternative medicine being practiced today, including reflexology, acupressure, acupuncture, chelation therapy, kinesiology, yoga, chiropractic, Feldenkrais, polarity therapy, detoxification, naturopathy, Chinese medicine, biofeedback, Ayurveda and osteopathy. For the practitioner or interested patient, there are...